Results 91 to 100 of about 320,703 (320)

Advances in Elemene Nanodelivery Systems: From Material Design to Disease Treatment

Rare Metals, EarlyView.
ABSTRACT Elemene (ELE) is a bioactive sesquiterpenoid extracted from traditional Chinese herbs, demonstrating broad‐spectrum antitumor, anti‐inflammatory, and analgesic properties with significant therapeutic potential. However, its clinical utility is constrained by inherent physicochemical limitations, including volatility and hydrophobicity, which ...
Xiao Wang, Jiatong Lin, Yi Peng, Zehua Wu, Yingying Liu, Wei Duan, Qiaolin Wei, Jia‐Wei Shen, Jiang‐Xing Chen, Yong Guo   +9 more
wiley   +1 more source

Acute pancreatitis associated with boceprevir: a case report

Brazilian Journal of Infectious Diseases, 2014
Approximately 170 million people are infected with hepatitis C, and the sustained virological response rate to treatment with pegylated interferon and ribavirin is 30–50%. In an attempt to improve the chances of cure, boceprevir is being added to therapy,
Juliana Miguel Bilar, Roberto José Carvalho-Filho, Carolina Frade Magalhães Girardin Pimentel Mota, Patricia da Silva Fucuta, Maria Lucia Cardoso Gomes Ferraz   +4 more
doaj   +1 more source

‘It’s been a long haul, a big haul, but we’ve made it’: hepatitis C virus treatment in post-transplant patients with virus recurrence: An interpretative phenomenological analysis [PDF]

, 2018
The lived experience of both interferon-based and new interferon-free treatments in patients with hepatitis C virus remains understudied. To explore their journey through hepatitis C virus treatment, we interviewed seven post-transplant patients with ...
Chouliara, Zoe, Dickson, Adele, Flowers, Paul, Hayes, Peter, Krzeczkowska, Anna   +4 more
core   +3 more sources

Regulatory T Cells and Nanomaterials: Dual Perspectives in Therapeutics and Immunomodulation

Small Science, EarlyView.
Tregs control immune tolerance but can also enable tumor escape. Nanomaterials can now expand or stabilize Tregs to treat autoimmunity and support transplantation or conversely disrupt tumor Tregs to boost antitumor immunity. We also discuss unintended Treg modulation by nanoparticles, safety and manufacturing challenges, and future translational ...
Yiyin Chen, Haibo Huang, Xiang Wang, Xinghao Yu, Ziyan Huang, Zhou Jin, Chen Chen, Yan Chen, Bruce R. Blazar, Yang Xu, Yunjie Lu   +10 more
wiley   +1 more source

Ten‐Year Follow‐Up After 96 Weeks Treatment With Peginterferon Plus Tenofovir in Hepatitis D (HIDIT‐II): Improved Clinical Outcome After Combination Therapy

United European Gastroenterology Journal, EarlyView.
ABSTRACT Background Chronic delta hepatitis represents a major health burden. Until recently, pegylated interferon‐alfa‐2a (PEG‐IFNα) therapy was the only treatment option for patients infected with hepatitis D virus (HDV). The aim of this study was to evaluate 10‐year long‐term clinical and virological outcomes after 96 weeks of treatment with PEG ...
Cihan Yurdaydin, Julia Kahlhöfer, Florin Alexandru Caruntu, Kendal Yalcin, Selim Gürel, Ulus S. Akarca, Kathrin Sprinzl, Hans H. Bock, Jan‐Hendrik Bockmann, George V. Papatheodoridis, Uta Merle, Münevver Demir, Svenja Hardtke, Onur Keskin, Ramazan Idilman, Markus Cornberg, Heiner Wedemeyer, Anika Wranke   +17 more
wiley   +1 more source

Safety and efficacy of treatment with pegylated interferon alpha-2a with ribavirin in chronic hepatitis C genotype 4

Annals of Hepatology, 2013
The hepatitis C virus (HCV) genotype is an important predictive outcome parameter for pegylated interferon plus ribavirin therapy. Most published therapeutic trials to date have enrolled mainly patients with HCV genotypes 1, 2 and 3. Limited studies have
Juan José Urquijo, Moisés Diago, M.D., Jaume Boadas, Ramón Planas, Ricard Solá, Juan Angel del Olmo, Javier Crespo, José Carlos Erdozaín, María Dolores Antón, Carlos Arocena, Dolores Suarez, Josep Giné, Josep M Barrera, Javier Gracia-Samaniego, Ricardo Perez, Blai Dalmau, Miguel Montoro   +16 more
doaj   +1 more source

Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer

Alimentary Pharmacology &Therapeutics, EarlyView.
In a cohort of 1596 liver cancer patients with either current or prior HBV infection undergoing systemic therapy in Hong Kong, the risk of HBV reactivation during immune checkpoint inhibitor treatment was low when adequate antiviral prophylaxis was administered, irrespective of HBV infection status.
Dorothy Cheuk‐Yan Yiu, Jimmy Che‐To Lai, Landon Long Chan, Grace Lai‐Hung Wong, Mandy Sze‐Man Lai, Vincent Wai‐Sun Wong, Yee‐Kit Tse, Henry Lik‐Yuen Chan, Stephen Lam Chan, Terry Cheuk‐Fung Yip   +9 more
wiley   +1 more source

Efficacy and Safety of In-Asia-manufactured Interferon Alpha-2b in Combination with Ribavirin for Therapy of Naïve Chronic Hepatitis C Patients: a Multicenter, Prospective, Open-Label Trial [PDF]

, 2009
Background: An open-label, multi center and non-comparative study was conducted to evaluate the efficacy and safety of a more affordable in-Asia-manufactured interferon á-2b product in combination with ribavirin to treat naïve chronic hepatitis C ...
Akbar, N. (Nurul), Gani, R. A. (Rino), Hasan, I. (Irsan), Lesmana, L. (Laurentius), Noer, S. (Sjaifoellah), Pridady, F. (FX), Sanityoso, A. (Andri), Soemarno, S. (Soemarno), Sulaiman, A. (Ali)   +8 more
core   +1 more source

When, which and how to switch: Navigating JAK inhibitors in myelofibrosis

British Journal of Haematology, EarlyView.
Navigating choice of JAK inhibitor (JAKi) therapy for patients with myelofibrosis who are JAKi‐naïve and for those who have previously been treated with a JAKi.
Jennifer O'Sullivan, Imran Omerdeen, Bethan Psaila   +2 more
wiley   +1 more source

In vitro IFN-α release from IFN-α- and pegylated IFN-α-loaded poly(lactic-co-glycolic acid) and pegylated poly(lactic-co-glycolic acid) nanoparticles [PDF]

, 2016
Aim: Interferon alpha (IFN-α) controlled release of nanoparticles was investigated under in vitro conditions. Materials & methods: IFN-α and pegylated IFN-α (PEG-IFN-α) were encapsulated by poly(lactic-co-glycolic acid) (PLGA) and pegylated PLGA ...
Feczkó, Tivadar, Fodorné Kardos, Andrea, Shubhra, Quazi T. H., Sivakumaran, Muttuswamy   +3 more
core   +1 more source